Back to search

Article

Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective study

2024-10-18

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>Luminal-type breast cancer (BC) was characterized as hormonal receptor positive human epidermal receptor 2 negative (HR+/HER2-), which comprises the majority of breast cancer (BC). The 70-gene signature (70-GS, MammaPrint) test is recommended for assessing recurrence risk and guiding adjuvant chemotherapy decisions in Luminal-type BC. Based on our previously est...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
256905df-5ec4-5732-a305-157ff1de8ed5
DOI
10.21203/rs.3.rs-4977540/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective studyDOI 10.21203/rs.3.rs-4977540/v1
Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patientsSemantic proximity
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.Semantic proximity
Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancerSemantic proximity
Miller–Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant ChemotherapySemantic proximity
A Nomogram for Predicting Mammaprint Results in Women with T1-3N0-1M0 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor-2-Negative Breast CancerSemantic proximity
High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancerSemantic proximity
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signatureSemantic proximity
<p class="MDPI12titleori1" style="mso-line-height-alt: 14.0pt;"><span style="mso-bidi-font-size: 18.0pt; mso-bidi-font-weight: bold;">MammaPrint™ Genetic Signature in the Brazilian Population, Analysis of Results and Clinical Outcomes (AGEMA-BRA) – Real World StudySemantic proximity
MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patientsSemantic proximity
Comparative Evaluation of a 28-Gene versus 70-Gene Panel for Recurrence Risk Prediction in Early-Stage HR-Positive/HER2-Negative Breast Cancer in Chinese WomenSemantic proximity
Clinical and Molecular Characteristics of ER-Positive Breast Cancer Tumors Identified as Ultralow Risk by the 70-Gene Signature in a Randomized Clinical TrialSemantic proximity
Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancerSemantic proximity
Select a neighboring publication to make it the new centre.